Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tarsus Pharmaceuticals Inc (NQ: TARS ) 26.17 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tarsus Pharmaceuticals Inc < Previous 1 2 Next > Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference August 28, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements August 08, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 July 29, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) is a Stock Spotlight on 4/15 April 15, 2024 Via Investor Brand Network Tarsus to Participate in Upcoming Investor Conferences May 29, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference May 09, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements May 08, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 May 01, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon April 23, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Participate at Upcoming Investor Conferences March 05, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis March 05, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Announces Pricing of $100.0 Million Public Offering March 01, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Announces Proposed $100.0 Million Public Offering February 29, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements February 27, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease February 22, 2024 TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 February 20, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference January 31, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Monday Session January 29, 2024 Via Investor Brand Network Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites December 11, 2023 TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Friday Session November 10, 2023 Via Investor Brand Network Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements November 09, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 November 01, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis September 06, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Present at Upcoming Investor Conferences August 30, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis August 24, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements August 10, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock August 01, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock July 31, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis July 25, 2023 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High July 20, 2023 Via Investor Brand Network < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.